BIIB stock forecast: what analysts expect
Wall Street analysts covering Biogen Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $235.57 — +12.8% versus the last price of $208.87. Targets reflect analyst opinion, not a guarantee.
BIIB historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in BIIB.
BIIB annual returns by year
Congress trading in BIIB
16 members of Congress have disclosed trading BIIB — 18 purchases and 18 sales worth an estimated $386,002. Most recent disclosure: Jun 5, 2026.
See who in Congress traded BIIB →Insider activity in BIIB
BIIB's own executives and directors have made 0 open-market purchases ($0) and 2 sales ($239,750) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 4, 2026.
| Aug 4, 2026 | Minor Lloyd | Director | Sell | $119,169 |
| Aug 3, 2026 | Minor Lloyd | Director | Sell | $120,581 |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Key Statistics
BIIB in plain English
- P/E ratio (36.3) — how many dollars you pay for each $1 of BIIB's yearly profit. That's a fairly normal range.
- ROE (4.58%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (8.32%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — BIIB doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
BIIB stock: frequently asked questions
What is Biogen Inc.'s stock price today?
Biogen Inc. (BIIB) last traded at $208.87 on the NASDAQ. Over the past 52 weeks the stock has traded between $129.40 and $219.72.
Is BIIB stock a buy or a sell?
Wall Street analysts' consensus rating on BIIB is "Buy", with an average 12-month price target of $235.57 — about +12.8% versus the current price of $208.87. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in BIIB 10 years ago be worth today?
A $1,000 investment in Biogen Inc. made 10 years ago would be worth about $683 today (dividends reinvested) — a total return of -32%, or -3.7% per year.
Does BIIB pay a dividend?
No — Biogen Inc. does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is BIIB's P/E ratio?
BIIB trades at a trailing price-to-earnings ratio of 36.3, and 12.6 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade BIIB stock?
Yes — 16 members of Congress have disclosed trades in BIIB under the STOCK Act, totaling 18 purchases and 18 sales worth an estimated $386,002.
What is Biogen Inc.'s ticker symbol?
Biogen Inc. trades under the ticker symbol BIIB on the NASDAQ.
Compare BIIB with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.